5-Fluorouracil Pharmacokinetics: Causes for Variability and Strategies for Modulation in Cancer Chemotherapy

References

• Duschinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropyrimidines. J Am Chem Soc 1957; 79: 4559–4560
   Web of Science ®Google Scholar
• Grem J L. 5-Fluoropyrimidines. Cancer Chemotherapy and Biotherapy, 2nd ed, BA Chabner, DL Longo. Lippincott-Raven Publishers, Philadelphia 1996; 146–211
   Google Scholar
• Codacci-Pisanelli G. Franchi F 5-Fluorouracil modulation in the chemotherapy of colorectal cancer. Ital J Gastroenterol 1994; 26: 369–376
   PubMedGoogle Scholar
• Sotos G A, Grogan L, Allegra C J. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994; 20: 11–49
   PubMed Web of Science ®Google Scholar
• Grem J L, McAtee N, Balk F. A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cis-platin in metastatic colorectal carcinoma. Cancer 1993; 72: 663–668
   PubMed Web of Science ®Google Scholar
• Grem J L, McAtee N, Steinberg S M. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma. Cancer Res 1993; 53: 4828–4836
   PubMed Web of Science ®Google Scholar
• Grem J L, Van Groeningen C J, Ismail A A. The role of inter-feron-α as a modulator of fluorouracil and leucovorin. Eur J Cancer 1995; 31A: 1316–1320
   PubMed Web of Science ®Google Scholar
• Poon M A, O'Connell M J, Moertel C G. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–1418
   PubMed Web of Science ®Google Scholar
• Van Groeningen C J, Peters G J, Pinedo H M. Modulation of fluorouracil toxicity with uridine. Sem Oucol 1992; 19: 148–154, Suppl 3
   PubMed Web of Science ®Google Scholar
• Arbuck S G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989; 63: 1036–1044
   PubMed Web of Science ®Google Scholar
• Cascinu S, Del Ferro E, Ligi M. A phase I trial of 5-fluorouracil, leucovorin and interferon-a2b administered by 24h infusion in metastatic colorectal carcinoma. Anti-Cancer Drugs 1996; 7: 520–524
   PubMed Web of Science ®Google Scholar
• Patel R, Newman E M, Villacorte D G. Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the children's cancer study group. Cancer Res 1991; 51: 4871–4875
   PubMed Web of Science ®Google Scholar
• Diasio R B, Hanis E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 1989; 16: 215–237
   PubMed Web of Science ®Google Scholar
• Heggie G D, Sommadossi J P, Cross D S. Clinical pharmaco-kinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203–2206
   PubMed Web of Science ®Google Scholar
• Cohen J L, Irwin L E, Marshall G J. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemother Rep 1974; 58: 723–731
   PubMedGoogle Scholar
• Christophidis N, Vajda F JE, Lucas I. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokin 1978; 3: 330–336
   PubMed Web of Science ®Google Scholar
• Abernethy D R, Alper J C, Wiemann M C. Oral 5-fluorouracil in psoriasis: pharmacokinetic-pharmacodynamic relationships. Pharmacology 1989; 39: 78–88
   PubMed Web of Science ®Google Scholar
• Phillips T A, Howell A, Grieve R J. Pharmacokinetics of oral and intravenous fluorouracil in humans. J Pharm Sci 1980; 69: 1428–1431
   PubMed Web of Science ®Google Scholar
• Almersjo O E, Gustavsson B G, Regardh C G. Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. Acta Pharmacol Toxicol 1980; 46: 329–336
   PubMedGoogle Scholar
• Fraile R J, Baker L H, Buroker T R. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40: 2223–2228
   PubMed Web of Science ®Google Scholar
• Sasaki H, Nakamura J, Konishi R. Intestinal absorption characteristics of 5-fluorouracil, ftorafur and 6-mercaptopurine in rats. Chem Pharm Bull 1986; 34: 4265–4272
   PubMed Web of Science ®Google Scholar
• Naguib F N, El Kouni M H, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissue. Cancer Res 1985; 45: 5404–5412
   Google Scholar
• Hahn R G, Moertel C G, Schutt A J. A double-blind comparison of intensive course 5-fluorouracil by oral and intravenous route in the treatment of colorectal carcinoma. Cancer 1975; 35: 1031–1035
   PubMed Web of Science ®Google Scholar
• Van Groeningen C J, Pinedo H M, Heddes J. Phamacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 1988; 48: 6956–6961
   PubMed Web of Science ®Google Scholar
• McDermott B J, Van den Berg H W, Murphy R F. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 1982; 9: 173–178
   PubMed Web of Science ®Google Scholar
• De Bruijn E A, Remeyer L, Tjaden U R. Non-linear pharmacokinetics of 5-fluorouracil as described by in vivo behavior of 5,6 dihydro-5-fluorouracil. Biochem Pharmacol 1986; 35: 2461–2465
   PubMed Web of Science ®Google Scholar
• Wagner J G, Gyves J W, Stetson P L. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 1986; 46: 1499–1506
   PubMed Web of Science ®Google Scholar
• Schaaf L J, Dobbs B R, Edwards I R. Nonlinear pharmacoki-netic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur J Clin Pharmacol 1987; 32: 411–418
   PubMed Web of Science ®Google Scholar
• Collins J M, Dedrick R L, King F G. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperi-toneal routes. Clin Pharmacol Ther 1980; 28: 235–246
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Watanabe J, Ozeki S. Sahvary excretion of 5-fluorouracil (5-FU). III. Non-linear kinetics of salivary excretion of 5-FU following bolus intravenous administration in rats. Chem Pharm Bull 1988; 36: 4547–4553
   PubMed Web of Science ®Google Scholar
• Petit E, Milano G, Levi F. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676–1679
   PubMed Web of Science ®Google Scholar
• Hrushesy W JM, Roemeling R V, Fraley E E. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. Sem Surg Oncol 1988; 4: 10–115
   Google Scholar
• Roemeling R V, Hrushesky W JM. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 1989; 7: 1710–1719
   PubMed Web of Science ®Google Scholar
• Daher G C, Harris B E, Willard E M. Biochemical basis for circadian-dependent metabolism of fluoropyrimidines. Ann NY Acad Sci 1991; 618: 350–361
   PubMed Web of Science ®Google Scholar
• Morrison G B, Bastian A, Rosa T D. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs For 1997; 24: 83–88
   Google Scholar
• Fleming R A, Milano G A, Gaspard M H. Dihydropyrimidine dehyclrogenase activity in cancer patients. Eur J Cancer 1993; 29A: 740–744
   PubMed Web of Science ®Google Scholar
• Huuyau P, Gay C, Chatelut E. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 1993; 85: 1602–1603
   PubMed Web of Science ®Google Scholar
• Tuchman M, Stoeckeler J S, Kiang D T. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985; 313: 245–249
   PubMed Web of Science ®Google Scholar
• Diasio R B, Beavers T L, Carpenter J T. Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 1988; 81: 47–51
   PubMed Web of Science ®Google Scholar
• Diasio R B, Beavers T L, Carpenter J T. Familial deficiency of dihydropyrimidine dehydrogenase—biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47–51
   PubMed Web of Science ®Google Scholar
• Harris B, Carpenter J T, Diasio R B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 1991; 68: 499–501
   PubMed Web of Science ®Google Scholar
• Lyss A P, Lilenbaum R C, Harris B E. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 1993; 11: 239–240
   PubMed Web of Science ®Google Scholar
• Diasio R B, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994; 12: 2239–2242
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhang R, Diasio R B. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995; 58: 512–522
   PubMed Web of Science ®Google Scholar
• Yokota H, Femandez-Salgeuro P, Fumya H. cDNA cloning and chromosome mapping of human dihyropyrimine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 1994; 269: 23192–23196
   PubMed Web of Science ®Google Scholar
• Albin N, Johnson M R, Diasio R B. cDNA cloning of bovine liver dihydropyrimidine dehydrogenase. DNA Seq 1996; 6: 243–250
   PubMed Web of Science ®Google Scholar
• Johnson M R, Wang K, Tillmanns S. Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res 1997; 57: 1660–1663
   PubMed Web of Science ®Google Scholar
• Takai S, Femandez-Salguero P, Kimura S. Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization. Genomics 1994; 24: 613–614
   PubMed Web of Science ®Google Scholar
• Meinsma R, Femandez-Salguero P, Van Kuilenburg A BP. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995; 14: l–6
   Google Scholar
• Vreken P, Van Kuilenburg A BP, Meinsma R. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 1996; 19: 645–654
   PubMed Web of Science ®Google Scholar
• Ridge S A, Brown O, McMurrough J. Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer 1997; 75: 178–179
   PubMed Web of Science ®Google Scholar
• Ridge S A, Sludden J, Wei X. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 1998; 77: 497–500
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhang R, Diasio R B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implications in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433–5438
   PubMed Web of Science ®Google Scholar
• Femandez-Salguero P, Gonzalez J, Etienne M. Correlation between catalytic activity and protein content for the polymor-phically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol 1995; 50: 1015–1020
   PubMed Web of Science ®Google Scholar
• Etienne M C, Lagrange J L, Dassonville O. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248–2253
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne M C, Cassuto-Viguier E. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10: 1171–1175
   PubMed Web of Science ®Google Scholar
• McMurrough J, McLeod H L. Analysis of the dihydropyrirnidinr dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 1996; 41: 425–427
   PubMed Web of Science ®Google Scholar
• Fleming R A, Milano G A, Etienne M C. No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. Br J Cancer 1992; 66: 668–672
   PubMed Web of Science ®Google Scholar
• Yoshida T, Araki E, Iigo M. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 1990; 26: 352–354
   PubMed Web of Science ®Google Scholar
• Fleming R A, Milano G A, Thyss A. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mono-nuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899–2902
   PubMed Web of Science ®Google Scholar
• Moertel C G, Schutt A, Reitemeir R J. A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 1972; 32: 2717–2719
   PubMed Web of Science ®Google Scholar
• Seifert P, Baker L H, Reed M L. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–128
   PubMed Web of Science ®Google Scholar
• Lokich J J, Ahlgren J D, Gullo J J. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology program study. J Clin Oncol 1989; 7: 425–432
   PubMed Web of Science ®Google Scholar
• Vokes E E, Schilsky R L, Choi K. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and cancer. Cancer 1989; 63: 30–36
   PubMed Web of Science ®Google Scholar
• Hansen R M, Quebbeman E, Anderson T. 5-Fluorouracil by protracted venous infusion: a review of current progress. Oncology 1989; 46: 245–250
   PubMed Web of Science ®Google Scholar
• Baker SD, Khor S P, Adjei A A. Pharmacokinetic oral bio-availability and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14: 3085–3096
   PubMed Web of Science ®Google Scholar
• Barr P J, Jones A S, Walker R T. Incorporation of 5-substituted uracil derivatives into nucleic acids. Part IV. The synthesis of 5-ethynyluracil. Nucleic Acids Res 1976; 3: 2845–2849
   PubMed Web of Science ®Google Scholar
• Porter D JT, Chestnut W G, Merrill B M. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992; 267: 5236–5242
   PubMed Web of Science ®Google Scholar
• Spector T, Hanington J A, Porter D JT. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993; 46: 2243–2248
   PubMed Web of Science ®Google Scholar
• Baccanari D P, Davis S T, Knick V C. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and anti-tumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993; 90: 11064–11068
   PubMed Web of Science ®Google Scholar
• Cao S, Rustum Y M, Spector T. 5-Ethynyluracil (776C85). Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994; 54: 1507–1510
   PubMed Web of Science ®Google Scholar
• Davis S T, Joyner S S, Baccanari D P. 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem Pharmacol 1994; 48: 233–236
   PubMed Web of Science ®Google Scholar
• Arellano M, Malet-Martino M, Martino R. Modulation of 5-fluorouracil metabolism by 5-ethynyluracil in the isolated perfused liver: prevention of formation of toxic compounds. Proc Am Assoc Cancer Res 1997; 38: 599, abstract
   Google Scholar
• Khor S P, Lucas S, Heish A Y. Effect on renal elimination of 5-fluorouracil and uracil in cancer patients. Proc Am Assoc Cancer Res 1996; 37: 371, abstract
   Google Scholar
• Pithvala Y K, Khor S P, Baker S. Chronic oral administration of 5-fluorouracil (5-FU) and 776C85 (GW776) in patients with solid tumors. Proc Am Assoc Cancer Res 1997; 38: 615, abstract
   Google Scholar
• Shepard D R, Maui S, Janisch L. Population pharmacokinetic determination of the effect of food on the pharmacokinetics of oral 5-fluorouracil (FU) and eniluracil (776C85, 776). Ann Oncol 1998; 9: 157, Suppl. 2)(abstract
   Web of Science ®Google Scholar
• Bums H, Schilsky R, Field S. Initial phase I trial of the dihydropyrimidine dehydrogenase inhibitor 5-ethynyluracil (776C85) plus 5-fluorouracil. Proc Am Soc Clin Oncol 1995; 14: 171, abstract
   Google Scholar
• Moran R G, Scanlon K L. Schedule-dependent enhancement of the cytotoxicity of fluoropyrirnidines to human carcinoma cells in the presence of folinic acid. Cancer Res 1991; 51: 4618–4623
   PubMed Web of Science ®Google Scholar
• Erlichman C, Fine S, Wong A. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469–475
   PubMed Web of Science ®Google Scholar
• Petrelli N, Herrera L, Rustum Y. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leuco-vorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal cancer. J Clin Oncol 1987; 5: 1559–1565
   PubMed Web of Science ®Google Scholar
• Nobile M T, Vidili M G, Sobrero A. 5-Fluorouracil (fu) alone or combined with high dose folinic acid (fa) in advanced colorectal cancer patients: a randomized trial. Proc Am Soc Clin Oncol 1988; 7: 97, abstract
   Google Scholar
• Fischel J I, Formento P, Spector T. Pharmacomodulation of 5-fluorouracil (FU) by the dihydropyrimidine dehydrogenase inactivator 776C85 (776C) combined with folinic acid (FA). Proc Am Assoc Cancer Res 1996; 37: 289, abstract
   Google Scholar
• Fischel J-L, Formento P, Etienne M-C. Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Biochem Phannacol 1997; 53: 1703–1709
   PubMed Web of Science ®Google Scholar
• Schilsky R, Bukowski R, Bums H. A phase II study of a five day regimen of oral 5-fluorouracil (5-FU) plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 271a, abstract
   Google Scholar
• Etienne M C, Cheradame S, Fischel J L. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydro-pyridimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663–1670
   PubMed Web of Science ®Google Scholar
• Diasio R B. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator. Oncology 1998; 3: 51–56
   Google Scholar
• McLeod H L, Sludden J, Murray G I. Characterization of dihydropyrimidine dehydrogenase in human colorectd tumours. Br J Cancer 1998; 77: 461–465
   PubMed Web of Science ®Google Scholar
• Danenberg K, Salonga D, Park J M. Dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) gene expressions identify a high percentage of colorectal tumors responding to 5-fluorouracil (5-FU). Proc Am Soc Clin Oncol 1998; 17: 258a
   Google Scholar
• Au J L, Sadée W. The pharmacology of Ftorafur (R, S-1–(tetrahy-dro-2-furanyl)-5-fluorouracil). Rec Res Cancer Res 1981; 76: 100–114
   PubMedGoogle Scholar
• Au J L, Wu A T, Friedman M A. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treatm Rep 1979; 63: 343–350
   PubMedGoogle Scholar
• Anttila M I, Sotaniemi E A, Kairaluoma M I. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 1983; 10: 150–153
   PubMed Web of Science ®Google Scholar
• Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. Acta Oncol 1987; 26: 433–436
   PubMed Web of Science ®Google Scholar
• Friedman M A, Ignoffo R J. A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treatm Rev 1980; 7: 205–213
   PubMed Web of Science ®Google Scholar
• Byfield J E, Hornbeck C L, Frankel S S. Relevance of the pharmacology of oral tegafur to its use as a 5-FU pro-drug. Cancer Treatm Rep 1985; 69: 545–652
   Google Scholar
• Taguchi T. Modulation of 5-FU and its related compounds. Jpn J Cancer Chemother 1997; 34: 195–205, Suppl. 1
   Google Scholar
• Ho D H, Covington W P, Pazdur R. Clinical pharmacology of combined oral uracil and ftorafur. Drug Met Disp 1992; 20: 936–940
   PubMed Web of Science ®Google Scholar
• Maehara Y, Kakeji Y, Ohno S. Scientific basis for the combination of tegafur with uracil. Oncology 1997; 11: 14–21
   PubMedGoogle Scholar
• Tang S, Hornbeck C L, Byfield J E. Enhanced accumulation of 5-fluorouracil in human tumors in athymic mice by co-administration of ftorafur and uracil. Int J Radiat Oncol Biol Phys 1984; 10: 1687–1691
   PubMed Web of Science ®Google Scholar
• Pazdur R, Covington W P, Brown. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU). Proc Am Soc Clin Oncol 1996; 15: 474, abstract
   Google Scholar
• Pazdur R, Lassere Y, Diaz-Canton E. Phase I trials of ura-cil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs 1996; 7: 728–733
   PubMed Web of Science ®Google Scholar
• Pazdur R. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Oncology 1997; 11: 35–39
   PubMedGoogle Scholar
• Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohoit investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22: 333–338
   PubMed Web of Science ®Google Scholar
• Cao S., Baccanari D P, Joyner S S. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur. a prodrug of 5-tluorouracil. Cancer Res 1995; 55: 6227–6230
   PubMed Web of Science ®Google Scholar
• Saltz L B, Leichman C G, Young C W. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin: an active oral regimen for advanced colorectal cancer. Cancer 1995; 75: 782–785
   PubMed Web of Science ®Google Scholar
• Carmichael J. UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer. Oncology 1997; 11: 50–52
   PubMedGoogle Scholar
• PaLdur R, Lassere Y, Rhodes V. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatmenl of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 1296–2300
   PubMedGoogle Scholar
• Sole L A, Ribas A, Gallardo E. A phase II study of pacli-taxel and oral tegafur modulated by oral low-dose folinic acid in anthracyclin-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1997; 16: 191a, abstract
   Google Scholar
• Pazdur R, Patt Y, Ajani J. Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cilllcer patients. Proc Am Soc Clin Oncol 1997; 16: 270a, abstract
   Google Scholar
• Pazdur R, Lassere Y, Diaz-Canton E. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule. Invest New Drugs 1997; 15: 123–128
   PubMed Web of Science ®Google Scholar
• Abad A, Navarro M, Sastre J. Phase II continuous UFT plus folinic acid in elderly patients with colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 280a, abstract
   Google Scholar
• Nogué M, Seguí MA, Batiste E. Phase II study of oral tegafur (TF) and low-dose oral leucovorin (LV) in advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1996; 15: 200, abstract
   Google Scholar
• Meropol N J, Rustum Y M, Petrelli N J. A phase I and phxmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 1996; 37: 581–586
   PubMed Web of Science ®Google Scholar
• Kim Y H, Shin S W, In B S. A phase II trial. Oral UFI and leucovorin in patients with advanced gastric carcinoma. Oncology 1997; 11: 119–123
   PubMedGoogle Scholar
• Pazdur R, Lassere Y, Diaz-Canton E. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. Cancer Invest 1998; 16: 145–151
   PubMed Web of Science ®Google Scholar
• Pazdur R, Lassere Y, Rhodes V. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1991; 12: 2296–2300
   Google Scholar
• Tatsumi K, Fukushima M, Shirasaka T. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748–755
   PubMedGoogle Scholar
• Shirasaka T, Nakano K, Takechi T. Antitumor activity of 1M-tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma ortho-topically implanted into nude rats. Cancer Res 1996; 56: 2602–2606
   PubMed Web of Science ®Google Scholar
• Takechi T, Nakano K, Uchida J. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997; 39: 205–211
   PubMed Web of Science ®Google Scholar
• Suzuki M, Sekiguchi I, Sato I. Combined effects of S-1, a new form of oral tegafur, plus modulators on ovarian cancer in nude rats. Chemotherapy 1996; 42: 452–458
   PubMed Web of Science ®Google Scholar
• Konno H, Tanaka T, Kanai T. Antitumor effect of S-1 (1M tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate) on the human colon cancer orthotopically transplanted into nude mice. Proc Am Assoc Cancer Res 1998; 39: 610, abstract
   Google Scholar
• Uchida J, Fukushima M, Shimamoto Y. Development of an advanced oral 5-FU analog, S-1: combination rationale of tegafur with two biomodulators to attain higher efficacy and reduced toxicity. Proc Am Assoc Cancer Res 1998; 39: 188, abstract
   Google Scholar
• Takechi T, Nakano K, Uchida J. Antitumor effect of S-1, a new formulation of oral tegafur, on human colon carcinoma implanted into nude rats. Proc Am Assoc Cancer Res 1998; 39: 609, abstract
   Google Scholar
• Horikoshi N, Mitachi Y, Sakata Y. S-1, new oral fluoro-pyrimidine is very active in patients with advanced gastric cancer (early phase II study). Proc Am Soc Clin Oncol 1996; 15: 206, abstract
   Google Scholar
• Taguchi T, Horikoshi N, Kinoshita H. Early phahe II study of S-l in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1996; 15: 121, abstract
   Google Scholar
• Fujii M, Kanzaki J, Satake B. Early phase II study of S-1 in patients with advanced head and neck cancer. Proc Am Soc Clin Oncol 1996; 15: 316, abstract
   Google Scholar
• Noordhuis P, Van Groeningen C J, Voom D. Pharmacokinetics (PK) of S-1, an oral formulation of Ftorafur (FT), oxonic acid (oxo) and 5-chloro-2, 4-dihydroxypyridine (CDHP) (molar ratio 1:1:0.4) in patients with solid tumors. Proc Am Assoc Cancer Res 1998; 39: 186, abstract
   Google Scholar
• Ishitsuka H, Miwa M, Ishikawa T. Capecitabine: an orally available fluoropyrimidine with tumor selective activity. Proc Am Assoc Cancer Res 1995; 36: 407, abstract
   Google Scholar
• Ishikawa T, Utoh M, Sawada N. XelodaTM (capecitabine): an orally available tumor-selective fluoropyrimidine carbamate. Proc Am Soc Clin Oncol 1997; 16: 208a, abstract
   Google Scholar
• Ishikawa T, Sekiguchi F, Fukase Y. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dhydropyrimidine dehy-drogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58: 685–690
   PubMed Web of Science ®Google Scholar
• Kono A, Hara Y, Sugata S. Activation of 5′-deoxy-5-fluo-rouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 1983; 31: 175–178
   PubMed Web of Science ®Google Scholar
• Miyadera K, Sumizawa T, Haraguchi M. Role of thymidine phosphorylase activity in the angiogenic effect of plateletderived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995; 55: 1687–1690
   PubMed Web of Science ®Google Scholar
• Eda H, Fujimoto K, Watanabe S. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32: 333–338
   PubMed Web of Science ®Google Scholar
• Ishitsuka H, Ishikawa T, Fukase T. Capecitabine and dThdase upregulators IFNγ or taxol showed synergistic activity in human cancer xenografts. Proc Am Assoc Cancer Res 1996; 37: 405, abstract
   Google Scholar
• Ishikawa T, Sawada N, Sekiguchi F. XelodaTM (capecitabine), a new oral fluoropyrimidine carhamate with an improved efficacy profile over other fluoropyrimidines. Roc Am Soc Clin Oncol 1997; 16: 226a, abstract
   Google Scholar
• Cao S, Lu K, Ishitsuka H. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol 1997; 16: 226a, abstract
   Google Scholar
• Twelves C, Budman D R, Creaven P J. Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 1996; 15: 476, abstract
   Google Scholar
• Bajetta E, Carnaghi C, Somma L. A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori 1996; 82: 450–452
   PubMed Web of Science ®Google Scholar
• Demario M, Ratain M J. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998; 16: 2557–2567
   PubMed Web of Science ®Google Scholar
• Finch R E, Bending M R, Lant A F. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol 1979; 7: 613–617
   PubMed Web of Science ®Google Scholar
• Finan P J, Chisholm E M, Woodhouse L. The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer. Eur J Surg Oncol 1987; 13: 349–353
   PubMedGoogle Scholar
• Hillcoat B L, McCulloch P B, Figueredo A T. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 1978; 38: 719–724
   PubMed Web of Science ®Google Scholar
• Erlichman C, Fine S, Eihakim T. Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treatm Rep 1986; 70: 903–904
   PubMedGoogle Scholar
• Spicer D V, Ardalan B, Daniels J R. Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 1988; 48: 459–461
   PubMed Web of Science ®Google Scholar
• Harris B E, Song R, Soong S J. Relationship between dihy-dropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197–201
   PubMed Web of Science ®Google Scholar
• Andersen L W, Parker R J, Collins J M. Gas chromato-graphic-mass spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions. J Chromatogr 1992; 581: 195
   PubMed Web of Science ®Google Scholar